Northeast Clinical Research Center | Bethlehem, PA

Research site

(Unclaimed)

Location

2014 City Line Road, Suite 103, Bethlehem, Pennsylvania, United States of America

Site insights

Top conditions

Top treatments

Lixivaptan

Bardoxolone Methyl

Selonsertib

BION-1301

Pegcetacoplan

UDCA

Iron

Sirolimus

Sofosbuvir

Ribavirin

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

11 of 41 total trials

A Study of Acthar Gel Alone or With Tacrolimus to Reduce Proteinuria in Fibrillary Glomerulopathy Patients (FACT)

A Multicenter, Comparative Safety and Efficacy Study of Acthar gel alone or in combination with oral Tacrolimus to reduce urinary proteinuria in pati...

Active, not recruiting

Fibrillary Glomerulonephritis

Drug: Acthar Gel 80 UNT/ML Injectable Solution

A Study of BION-1301 in Adults With IgA Nephropathy

Safety and Efficacy of BION-1301 in Adults with IgA Nephropathy

Enrolling

Immunoglobulin A Nephropathy

IgA Nephropathy

Drug: Placebo

Drug: BION-1301

A Study of RGLS8429 in Patients With Autosomal Dominant Polycystic Kidney Disease

Primary Objectives* To assess the safety and tolerability of RGLS8429* To assess the impact of RGLS8429 on ADPKD biomarkersSecondary Objectives* To a...

Enrolling

ADPKD

Polycystic Kidney, Autosomal Dominant

Drug: Placebo

Drug: RGLS8429

A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic Kidney Disease (FIND-CKD)

Researchers are looking for a better way to treat people who have non-diabetic chronic kidney disease (non-diabetic CKD). The trial treatment, finere...

Active, not recruiting

Non-diabetic Chronic Kidney Disease

Drug: Finerenone (BAY94-8862)

Drug: Placebo

An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis (VALE)

This study is designed as a long-term extension to Study APL2-C3G-310, and is being conducted to establish the long-term safety and efficacy of pegce...

Active, not recruiting

Membranoproliferative Glomerulonephritis (MPGN)

Membranoproliferative Glomerulonephritis

Drug: Pegcetacoplan

Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (FXI Hemodialysis Study) (MK-2060-007)

The purpose of this study is to evaluate the efficacy and safety of two different doses of MK-2060 (a monoclonal antibody against Factor XI) in end s...

Active, not recruiting

End-Stage Renal Disease

End-Stage Kidney Disease

Drug: MK-2060

Drug: Placebo

Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis (VALIANT)

This is a Phase 3 study to assess the efficacy and safety of twice-weekly subcutaneous (SC) doses of pegcetacoplan compared to placebo in patients wi...

Active, not recruiting

Membranoproliferative Glomerulonephritis (MPGN)

Membranoproliferative Glomerulonephritis

Other: Placebo

Drug: Pegcetacoplan

Renasight Clinical Application, Review and Evaluation (RenaCARE) Study

This study is an open-label, multi-center study evaluating the clinical utility of Renasight in the diagnosis and management of kidney disease.

Active, not recruiting

Kidney Diseases

Diagnostic Test: Renasight

Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN)

Multicenter study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of BION-1301 in healthy volunteers...

Active, not recruiting

IgA Nephropathy

Drug: BION-1301 Multiple Doses

Drug: Placebo Multiple Doses

Seladelpar in Subjects With Primary Biliary Cholangitis (PBC)

An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects with Primary Biliary Cholangitis (PBC)

Enrolling

Primary Biliary Cirrhosis

Drug: Seladelpar 5 mg Capsule

Drug: Seladelpar 10 mg Capsule

ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation

This study is conducted to see if ziltivekimab reduces the risk of having cardiovascular events (for example heart attack and stroke) in people with...

Enrolling

Chronic Kidney Disease

Inflammation

Drug: Placebo (Ziltivekimab B)

Drug: Placebo (Ziltivekimab C)